Improvement of a 'Leaky' Intestinal Barrier

Digestive Diseases

Volumn 35, Issue 1-2, 2017, Pages 21-24

  Stange, Eduard F ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Defensins; Inflammatory bowel disease; Intestinal barrier; Mucus

Indexed keywords

DEFENSIN; LACTULOSE; MANNITOL; MURAMYL DIPEPTIDE; PROBIOTIC AGENT; STABILIZING AGENT;

ADAPTIVE IMMUNITY; ARTICLE; AUTOPHAGY; BACTERIUM ADHERENCE; CELL DIFFERENTIATION; CROHN DISEASE; EXPERIMENTAL COLITIS; GOBLET CELL; HUMAN; INFLAMMATION; INTESTINE; METAPLASIA; MUCUS; NONHUMAN; PANETH CELL; PRIORITY JOURNAL; ULCERATIVE COLITIS; ANIMAL; MICROBIOLOGY; PATHOLOGY;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INTESTINES;

EID: 85011635913     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000449078     Document Type: Article

References (17)

1. Johansson ME, Phillipson M, Petersson J, et al: The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008; 105: 15064-15069.
2. Antoni L, Nuding S, Weller D, et al: Human colonic mucus is a reservoir for antimicrobial peptides. J Crohns Colitis 2013; 7:e652-e664.
3. Antoni L, Nuding S, Wehkamp J, Stange EF: Intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2014; 20: 1165-1179.
4. Bevins CL, Salzman NH: Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 2011; 9: 356-368.
5. VanDussen KL, Liu TC, Li D, Towfic F, et al: Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's disease. Gastroenterology 2014; 146: 200-209.
6. Wehkamp J, Harder J, Weichenthal M, et al: NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alphadefensin expression. Gut 2004; 53: 1658-1664.
7. Thachil E, Hugot JP, Arbeille B, et al: Abnormal activation of autophagy-induced crinophagy in Paneth cells from patients with Crohn's disease. Gastroenterology 2012; 142: 1097-1099.e4.
8. Gunther C, Martini E, Wittkopf N, et al: Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477: 335-339.
9. Wehkamp J, Stange EF: Paneth's disease. J Crohns Colitis 2010; 4: 523-531.
10. Courth LF, Ostaff MJ, Mailander-Sanchez D, et al: Crohn's disease-derived monocytes fail to induce Paneth cell defensins. Proc Natl Acad Sci U S A 2015; 112: 14000-14005.
11. Peyrin-Biroulet L, Beisner J, Wang G, et al: Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A 2010; 107: 8772-8777.
12. Nuding S, Fellermann K, Wehkamp J, et al: Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007; 56: 1240-1247.
13. Swidsinski A, Ladhoff A, Pernthaler A, et al: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
14. Prantera C, Lochs H, Grimaldi M, et al: Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-481.e4.
15. Wehkamp J, Harder J, Wehkamp K, et al: NF-kappaB-and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004; 72: 5750-5758.
16. Kruis W, Fric P, Pokrotnieks J, et al: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623.
17. Karner M, Kocjan A, Stein J, et al: First multicenter study of modified release phosphatidylcholine 'LT-02' in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol 2014; 109: 1041-1051.